TP53 and B-cell chronic lymphocytic leukemia: Based on the observations that PEITC was able to induce significant CLL cell death in primary human CLL cells in vitro and in leukemic splenocytes in CLL mice, we further evaluated the in vivo therapeutic activity of PEITC in CLL mice with TCL1-Tg:p53−/− genotype.